Replimune Group (NASDAQ:REPL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Saturday.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

REPL has been the subject of a number of other reports. BMO Capital Markets began coverage on shares of Replimune Group in a research report on Tuesday, August 14th. They set an “outperform” rating and a $31.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Replimune Group in a report on Tuesday, August 14th. They set an “overweight” rating and a $26.00 target price for the company. Finally, Leerink Swann began coverage on shares of Replimune Group in a report on Tuesday, August 14th. They set an “outperform” rating and a $25.00 target price for the company.

REPL opened at $14.32 on Friday. Replimune Group has a 12-month low of $10.52 and a 12-month high of $23.55.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). On average, analysts forecast that Replimune Group will post -1.21 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Replimune Group during the third quarter worth $8,425,000. Emerald Advisers Inc. PA acquired a new position in shares of Replimune Group during the third quarter worth $9,951,000. Victory Capital Management Inc. acquired a new position in shares of Replimune Group during the third quarter worth $2,066,000. Omega Fund Management LLC acquired a new position in shares of Replimune Group during the third quarter worth $82,166,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Replimune Group during the third quarter worth $319,000. 55.75% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: How a Put Option Works

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.